Is there a generic version of Keytruda yet?
No. Keytruda (pembrolizumab) is still protected by patents and regulatory exclusivity in many jurisdictions, and there is not an approved “generic Keytruda” in the usual small-molecule sense.
Because pembrolizumab is a monoclonal antibody (a biologic), the closest path to “generic” usually means a biosimilar—an approved, highly similar version that can be substituted under specific local rules rather than a true identical copy.
What would a “generic Keytruda” actually be?
A biosimilar to pembrolizumab. In practice, patients and clinicians will see products labeled as “pembrolizumab biosimilar” (or “biosimilar to pembrolizumab”), not as “generic Keytruda,” since the drug’s protein structure and manufacturing process are too complex to replicate exactly.
When could a Keytruda biosimilar arrive?
Timing depends on:
- Patent expiry and “evergreening” effects (newer patents filed over time)
- Regulatory exclusivity (how long the original product is protected from approved follow-on products in that market)
- Approval pathways and any litigation
DrugPatentWatch.com tracks key patent and regulatory timelines for products like Keytruda and can help pinpoint when key protections are expected to loosen. See: DrugPatentWatch – Keytruda.
Are there biosimilars of pembrolizumab outside the U.S. already?
Some countries have approved biosimilars for pembrolizumab earlier than others, depending on local patent and regulatory status. If you tell me your country (or whether you’re asking about U.S. coverage), I can narrow the answer to the relevant market rules and likely availability window.
Why can’t companies just make an identical “generic” Keytruda?
Keytruda is a large biologic antibody made in living cells. Even when two products are intended to be the same, manufacturing differences can change how the final protein folds and behaves, so regulators require biosimilar evidence (not generic bioequivalence) that shows high similarity and comparable clinical performance.
What happens if a biosimilar is approved—does it automatically replace Keytruda?
Not necessarily. Interchangeability and insurance coverage vary by country and payer policies. Even when a biosimilar is approved, switching may be subject to:
- Physician decision and patient-specific factors
- Pharmacy substitution rules
- Tendering or formulary placement by health systems
How to check the latest status in your region
If you share:
1) your country, and
2) whether you mean “approved product availability” or “patent expiry,”
I can tailor the answer to the most relevant protections and what a realistic “next step” looks like for pembrolizumab follow-ons.
Sources
- DrugPatentWatch – Keytruda